TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL Share Price

Certificat

DE000SW9K797

Market Closed - Boerse Frankfurt Warrants 01:14:54 29/05/2024 am IST
1.64 EUR +13.89% Intraday chart for TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL
Current month+53.77%
1 month+61.39%
Date Price Change
28/24/28 1.63 +13.19%
27/24/27 1.44 -5.26%
24/24/24 1.52 0.00%
23/24/23 1.52 +4.83%
22/24/22 1.45 +5.84%

Real-time Boerse Frankfurt Warrants

Last update May 29, 2024 at 01:14 am IST

More quotes

Static data

Product typeCertificat Turbo
Buy / SellPUT
Underlying BIOMARIN PHARMACEUTICAL INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SW9K79
ISINDE000SW9K797
Date issued 26/04/2024
Strike 91.13 $
Maturity Unlimited
Parity 10 : 1
Emission price 0.41
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.64
Lowest since issue 0.57

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
74.43 USD
Average target price
109.3 USD
Spread / Average Target
+46.88%
Consensus